Previous close | 43.11 |
Open | 43.11 |
Bid | 28.60 |
Ask | 32.80 |
Strike | 110.00 |
Expiry date | 2025-01-17 |
Day's range | 43.11 - 43.11 |
Contract range | N/A |
Volume | |
Open interest | 21 |
Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the first quarter of fiscal year 2024, which include the consolidated financial results for GRAIL.
AbCellera Biologics (ABCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Evaluate the expected performance of Illumina (ILMN) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.